Shilpa Medicare Ltd

Shilpa Medicare’s Unit VI Clears USFDA Inspection 🏭✅ – Global Expansion on Track

- Unit VI in Bengaluru received USFDA’s EIR with VAI classification after inspection (Oct 24–30, 2024).

- Facility approved by EMA (Europe), MHRA (UK), SFDA (Saudi Arabia), and TGA (Australia).

- Specializes in complex dosage forms: Oral Dissolving Films & Transdermal Systems.

- Currently supplies Oral Film products to the US and other markets.

- Transdermal products filed for approval in Europe, signaling future growth.